問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1738Cases

2024-08-01 - 2028-03-31

Phase II

A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)

  • Condition/Disease

    Lung Cancer

  • Test Drug

    Osimertinib tablets 40 mg

Participate Sites
7Sites

Recruiting7Sites

2019-02-01 - 2026-11-30

Phase III

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)

  • Condition/Disease

    Advanced Epithelial Ovarian Cancer (EOC)

  • Test Drug

    KEYTRUDA®/LYNPARZA®

Participate Sites
8Sites

Recruiting8Sites

2023-04-22 - 2026-10-30

Phase III

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

  • Condition/Disease

    Geographic Atrophy

  • Test Drug

    Tinlarebant

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting2Sites

Terminated1Sites

2023-07-01 - 2030-06-30

Phase II/III

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
8Sites

Recruiting8Sites

2024-07-01 - 2027-08-31

Phase I/II

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

  • Condition/Disease

    Nonsquamous Non-small Cell Lung Cancer

  • Test Drug

    Vudalimab

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2022-05-10 - 2026-08-04

Phase III

HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    Patritumab Deruxtecan (U3-1402)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2022-12-14 - 2026-01-01

Phase III

Active
A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients

  • Condition/Disease

    gout

  • Test Drug

    Epaminurad

Participate Sites
13Sites

Not yet recruiting1Sites

Recruiting12Sites

2023-12-24 - 2027-03-01

Phase II

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

  • Condition/Disease

    Adenocarcinoma of Lung

  • Test Drug

    LP-300

Participate Sites
5Sites

Recruiting5Sites

2024-01-01 - 2027-07-31

Phase II

BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Head and Neck Neoplasms

  • Test Drug

    TransCon IL-2 β/γTransCon TLR7/8 Agonist

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2029-09-30

Phase III

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

  • Condition/Disease

    Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Test Drug

    PF-06821497 (MEVROMETOSTAT)EnzalutamideDocetaxel

Participate Sites
6Sites

Recruiting6Sites

1 95 96 97 98 99 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB